1. Home
  2. OIS vs RLMD Comparison

OIS vs RLMD Comparison

Compare OIS & RLMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Oil States International Inc.

OIS

Oil States International Inc.

HOLD

Current Price

$8.08

Market Cap

552.6M

Sector

Industrials

ML Signal

HOLD

Logo Relmada Therapeutics Inc.

RLMD

Relmada Therapeutics Inc.

HOLD

Current Price

$6.69

Market Cap

661.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
OIS
RLMD
Founded
1995
2004
Country
United States
United States
Employees
N/A
N/A
Industry
Metal Fabrications
Biotechnology: Pharmaceutical Preparations
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
552.6M
661.9M
IPO Year
2000
2012

Fundamental Metrics

Financial Performance
Metric
OIS
RLMD
Price
$8.08
$6.69
Analyst Decision
Buy
Strong Buy
Analyst Count
2
5
Target Price
$14.00
$12.40
AVG Volume (30 Days)
744.0K
1.5M
Earning Date
05-05-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
45.28
EPS
0.02
N/A
Revenue
$1,088,133,000.00
$13,070.00
Revenue This Year
$3.12
N/A
Revenue Next Year
$5.89
N/A
P/E Ratio
$397.50
N/A
Revenue Growth
62.26
154.83
52 Week Low
$4.75
$0.55
52 Week High
$14.50
$8.00

Technical Indicators

Market Signals
Indicator
OIS
RLMD
Relative Strength Index (RSI) 37.21 47.20
Support Level $7.77 $6.17
Resistance Level $8.71 $7.46
Average True Range (ATR) 0.27 0.45
MACD 0.03 0.03
Stochastic Oscillator 39.83 60.47

Price Performance

Historical Comparison
OIS
RLMD

About OIS Oil States International Inc.

Oil States International Inc is a provider of manufactured products and services to customers in the energy, military and industrial sectors. The company operates through three business segments - Offshore Manufactured Products, Completion and Production Services and Downhole Technologies. Its customers include many national oil and natural gas companies, and independent oil and natural gas companies, offshore drilling companies and other oilfield service, defense and industrial companies.

About RLMD Relmada Therapeutics Inc.

Relmada Therapeutics Inc is a clinical-stage, publicly traded biotechnology company focused on the development of NDV-01 and sepranolone. NDV-01 is a novel, controlled-release intravesical formulation of gemcitabine and docetaxel. NDV-01 is currently in a Phase 2 clinical trial in Isreal to assess its safety and efficacy in patients with aggressive forms of non-muscle invasive bladder cancer (NMIBC). Sepranolone is a novel neurosteroid epimer of allopregnanolone. sepranolone is being developed for the potential treatment of Prader-Willi Syndrome, Tourette Syndrome, excessive tremor and other diseases related to excessive GABAergic activity.

Share on Social Networks: